1-6 of 6
Darrell R. Borger
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

Free
Martin H. Voss, Cinta Hierro, Rebecca S. Heist, James M. Cleary, Funda Meric-Bernstam, Josep Tabernero, Filip Janku, Leena Gandhi, A. John Iafrate, Darrell R. Borger, Nobuya Ishii, Youyou Hu, Yulia Kirpicheva, Valerie Nicolas-Metral, Anna Pokorska-Bocci, Anne Vaslin Chessex, Claudio Zanna, Keith T. Flaherty, Jose Baselga
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (9): 2699–2707.
https://doi.org/10.1158/1078-0432.CCR-18-1959
Published: 01 May 2019
View articletitled, A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
Open the PDF for A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations in another window
Includes: Supplementary data
Journal Articles

Dual HER2 Targeting Impedes Growth of HER2 Gene–Amplified Uterine Serous Carcinoma Xenografts

Free
Jolijn W. Groeneweg, Silvia F. Hernandez, Virginia F. Byron, Celeste M. DiGloria, Hector Lopez, Vanessa Scialabba, Minji Kim, Ling Zhang, Darrell R. Borger, Rosemary Tambouret, Rosemary Foster, Bo R. Rueda, Whitfield B. Growdon
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (24): 6517–6528.
https://doi.org/10.1158/1078-0432.CCR-14-1647
Published: 14 December 2014
View articletitled, Dual HER2 Targeting Impedes Growth of HER2 Gene–Amplified Uterine Serous Carcinoma Xenografts
Open the PDF for Dual HER2 Targeting Impedes Growth of HER2 Gene–Amplified Uterine Serous Carcinoma Xenografts in another window
Includes: Supplementary data
Journal Articles

Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas

Free
Hiroaki Wakimoto, Shota Tanaka, William T. Curry, Franziska Loebel, Dan Zhao, Kensuke Tateishi, Juxiang Chen, Lindsay K. Klofas, Nina Lelic, James C. Kim, Dora Dias-Santagata, Leif W. Ellisen, Darrell R. Borger, Sarah-Maria Fendt, Matthew G. Vander Heiden, Tracy T. Batchelor, A. John Iafrate, Daniel P. Cahill, Andrew S. Chi
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (11): 2898–2909.
https://doi.org/10.1158/1078-0432.CCR-13-3052
Published: 29 May 2014
View articletitled, Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas
Open the PDF for Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas in another window
Includes: Supplementary data
Journal Articles

Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma

Free
Darrell R. Borger, Lipika Goyal, Thomas Yau, Ronnie T. Poon, Marek Ancukiewicz, Vikram Deshpande, David C. Christiani, Hannah M. Liebman, Hua Yang, Hyeryun Kim, Katharine Yen, Jason E. Faris, A. John Iafrate, Eunice L. Kwak, Jeffrey W. Clark, Jill N. Allen, Lawrence S. Blaszkowsky, Janet E. Murphy, Supriya K. Saha, Theodore S. Hong, Jennifer Y. Wo, Cristina R. Ferrone, Kenneth K. Tanabe, Nabeel Bardeesy, Kimberly S. Straley, Sam Agresta, David P. Schenkein, Leif W. Ellisen, David P. Ryan, Andrew X. Zhu
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (7): 1884–1890.
https://doi.org/10.1158/1078-0432.CCR-13-2649
Published: 31 March 2014
View articletitled, Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma
Open the PDF for Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma in another window
Includes: Supplementary data
Journal Articles

Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment

Free
Valentina Nardi, Peter M. Sadow, Dejan Juric, Dave Zhao, Arjola K. Cosper, Kristin Bergethon, Vanessa L. Scialabba, Julie M. Batten, Darrell R. Borger, Anthony John Iafrate, Rebecca S. Heist, Donald P. Lawrence, Keith T. Flaherty, Johanna C. Bendell, Daniel Deschler, Yi Li, Lori J. Wirth, Dora Dias-Santagata
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (2): 480–490.
https://doi.org/10.1158/1078-0432.CCR-12-1842
Published: 16 January 2013
View articletitled, Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment
Open the PDF for Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment in another window
Journal Articles

Activation of PI3K Signaling in Merkel Cell Carcinoma

Free
Valentina Nardi, Youngchul Song, Juan A. Santamaria-Barria, Arjola K. Cosper, Quynh Lam, Anthony C. Faber, Genevieve M. Boland, Beow Y. Yeap, Kristin Bergethon, Vanessa L. Scialabba, Hensin Tsao, Jeffrey Settleman, David P. Ryan, Darrell R. Borger, Atul K. Bhan, Mai P. Hoang, Anthony J. Iafrate, James C. Cusack, Jeffrey A. Engelman, Dora Dias-Santagata
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (5): 1227–1236.
https://doi.org/10.1158/1078-0432.CCR-11-2308
Published: 01 March 2012
View articletitled, Activation of PI3K Signaling in Merkel Cell Carcinoma
Open the PDF for Activation of PI3K Signaling in Merkel Cell Carcinoma in another window
Includes: Supplementary data